|
Oct 24
|
Palatin Announces Closing of $5 Million Registered Direct Offering
|
|
Oct 23
|
Palatin Announces $5 Million Registered Direct Offering
|
|
Oct 19
|
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
|
|
Oct 18
|
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
|
|
Aug 10
|
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
|
|
Aug 8
|
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
|
|
Aug 7
|
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
|
|
Aug 4
|
Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
|